**Supplemental Materials**

**Figure 2 Classification of *Clostridium difficile* Infection Severity and Treatment Recommendations**

IDSA= Infectious Diseases Society of America (IDSA)

SHEA= Society for Healthcare Epidemiology of America

Scr= Serum Creatinine

PO= Per Os

IV= Intravenous

Q= Every

**Figure 3 *Clostridium difficile* Infection Best Practice Alert**

**Figure 4 *Clostridium difficile* Infection Guideline-based Treatment Prescribing**

**Table 2 Clinical Characteristics**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Pre BPA/Order Set**  **N=66** | **Post BPA/Order Set**  **N=65** |
| **Age at CDI diagnosis (Median (IQR))** | **57 (42-69)** | **60 (52-67)** |
| **Gender**  **Female, n (%)** | **38 (57.6)** | **28 (43)** |
| **Risk Factors for CDI, n (%)**  **Immunocompromised**  **Cancer\***  **HIV**  **Immunosuppressant PTA**  **Antibiotics PTA** | **35 (53)**  **18 (27.3)**  **3 (4.5)**  **14 (21.2)**  **29 (43.9)** | **21 (32.3)**  **7 (10.8)**  **0 (0)**  **14 (21.5)**  **21 (32.3)** |
| **History of CDI, n (%)**  **1-2 previous occurrences**  **>2 occurrences** | **3 (4.5)**  **2**  **1** | **10 (15.4)**  **9**  **1** |
| **Toxigenic CDI\*\*, n (%)** | **37 (56.1)** | **33 (50.7)** |
| **CDI Severity, n (%)**  **Mild-Moderate**  **Severe**  **Severe Complicated**  **Recurrent (>1 recurrence)** | **46 (69.7)**  **18 (27.3)**  **1 (1.5)**  **1 (1.5)** | **49 (75.4)**  **12 (18.5)**  **1 (1.5)**  **3 (4.6)** |
| **CDI Initial Treatment, n (%)**  **Metronidazole monotherapy**  **Vancomycin monotherapy**  **Metronidazole and vancomycin**  **Fidaxomicin** | **46 (69.7)**  **14 (21.2)**  **5 (7.6)**  **1 (1.5)** | **49 (75.4)**  **7 (10.8)**  **9 (13.8)**  **0 (0)** |
| **CDI Treatment Duration**  **(Median (IQR))** | **11 (6.75-14)** | **10 (8 - 14)** |

\*Active cancer treatment

BPA= Best Practice Alert

CDI= *Clostridium difficile* Infection

HIV= Human Immunodeficiency Virus

PTA= Prior to Admission

**\*\*** As determined by toxins A and B enzyme immunoassay